Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and the Blood and Marrow Transplant Clinical Trials Network (BMT...

Related Keywords

Rockville ,Wisconsin ,United States ,Japan ,China ,Tokyo ,Green Bay ,Medical College Of Wisconsin ,Germany ,America ,American ,Marym Horowitz ,Ahsan Arozullah ,Naoki Okamura ,Head Of Oncology Development ,Marrow Transplant Clinical Trials Network ,Marrow Transplant Research ,College Of Wisconsin With ,National Cancer Institute ,Prnewswire Astellas Pharma Inc ,National Heart ,International Blood ,American Cancer Society ,Astellas Pharma Us Inc ,Core Transplant Centers Consortia ,Astellas Pharma Inc ,Lab Abnormalities ,Emmes Company ,European Hematology Association ,National Institutes Of Health ,College Of Wisconsin ,School Of Pharmacy ,Blood Institute ,National Marrow Donor Program ,Kotobuki Pharmaceutical Co Ltd ,Clinical Research Organization ,Leukemia Group ,Congress Press Briefing ,Hematology Association ,Hybrid Congress Press Briefing ,Hazard Ratio ,Confidence Interval ,North American ,Senior Vice President ,Oncology Development ,Principal Investigator ,Important Safety ,Reversible Encephalopathy Syndrome ,Abnormalities Shifts ,Inducers Concomitant ,Sigma Nonspecific Receptor Concomitant ,Full Prescribing Information ,Trial The Phase ,North America ,Acute Myeloid Leukemia ,Astellas Pharma ,Focus Area Approach ,National Institutes ,Medical College ,National Marrow Donor ,Marrow Transplant ,Wisconsin With ,What Is Acute Myeloid Leukemia ,Key Statistics ,Eurj Cancer ,